Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Lyratzopoulos, Georgios
Hoy, Andrew R.
Veeramootoo, Darmarajah
Shanmuganathan, Nava V.
and
Campbell, Bruce
2008.
Influence of expert clinical adviser characteristics on opinions about interventional procedures.
International Journal of Technology Assessment in Health Care,
Vol. 24,
Issue. 02,
p.
166.
Barbieri, Marco
Hawkins, Neil
and
Sculpher, Mark
2009.
Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision-Making about the Funding of Health Technologies.
Value in Health,
Vol. 12,
Issue. 2,
p.
193.
van de Klippe, C. J.
and
Knottnerus, J. A.
2010.
Wie betaalt, bepaalt?.
Huisarts en wetenschap,
Vol. 53,
Issue. 12,
p.
683.
Klippe, C.J.
and
Knottnerus, J.A.
2010.
Wie betaalt, bepaalt?.
Huisarts en wetenschap,
Vol. 2010,
Issue. 12,
p.
683.
Hoch, Jeffrey S.
2010.
Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer.
p.
543.
Carroll, Christopher
Kaltenthaler, Eva
FitzGerald, Patrick
Boland, Angela
and
Dickson, Rumona
2011.
A thematic analysis of the strengths and weaknesses of manufacturers’ submissions to the NICE Single Technology Assessment (STA) process.
Health Policy,
Vol. 102,
Issue. 2-3,
p.
136.
Roberts, Mark
Russell, Louise B.
Paltiel, A. David
Chambers, Michael
McEwan, Phil
and
Krahn, Murray
2012.
Conceptualizing a Model.
Medical Decision Making,
Vol. 32,
Issue. 5,
p.
678.
Roberts, Mark
Russell, Louise B.
Paltiel, A. David
Chambers, Michael
McEwan, Phil
and
Krahn, Murray
2012.
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2.
Value in Health,
Vol. 15,
Issue. 6,
p.
804.
Fischer, Katharina Elisabeth
2012.
A systematic review of coverage decision-making on health technologies—Evidence from the real world.
Health Policy,
Vol. 107,
Issue. 2-3,
p.
218.
Afzali, Hossein Haji Ali
Karnon, Jonathan
and
Merlin, Tracy
2013.
Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions.
Medical Decision Making,
Vol. 33,
Issue. 3,
p.
325.
Yong, Jean H. E.
Beca, Jaclyn
and
Hoch, Jeffrey S.
2013.
The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada.
PharmacoEconomics,
Vol. 31,
Issue. 3,
p.
229.
Catalá-López, Ferrán
Sanfélix-Gimeno, Gabriel
Ridao, Manuel
Peiró, Salvador
and
Keyhani, Salomeh
2013.
When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins.
PLoS ONE,
Vol. 8,
Issue. 7,
p.
e69462.
John-Baptiste, Ava A.
Wu, Wei
Rochon, Paula
Anderson, Geoffrey M.
Bell, Chaim M.
and
Miller, Todd W.
2013.
A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer.
PLoS ONE,
Vol. 8,
Issue. 5,
p.
e62614.
Hoch, Jeffrey S.
2013.
Operations Research and Health Care Policy.
Vol. 190,
Issue. ,
p.
399.
Johannesen, Kasper M.
Claxton, Karl
Sculpher, Mark J.
and
Wailoo, Allan J.
2018.
How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework.
Health Economics,
Vol. 27,
Issue. 2,
Love-Koh, James
Cookson, Richard
Gutacker, Nils
Patton, Thomas
and
Griffin, Susan
2019.
Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
Value in Health,
Vol. 22,
Issue. 5,
p.
518.